BioCentury
ARTICLE | Clinical News

Loxo buy a step closer to paying off as Lilly heads to FDA with RET inhibitor

September 9, 2019 11:17 PM UTC

Lilly could have the best-in-class and first-in-class RET fusion inhibitor as it heads to FDA this year with the lead asset in its $8 billion acquisition of Loxo Oncology Inc.

Eli Lilly and Co. (NYSE:LLY) announced data on Monday from the Phase I/II LIBRETTO-001 trial for selpercatinib (LOXO-292) to treat ret proto-oncogene (RET) fusion-positive non-small cell lung cancer (NSCLC) in patients who have relapsed after platinum therapy. Among 105 patients in the single-arm Phase II portion of the trial, the objective response rate (ORR) was 68%; in a subset of 11 patients with brain metastases, the ORR was 91%. ...

BCIQ Company Profiles

Eli Lilly and Co.

BCIQ Target Profiles

Ret proto-oncogene (RET)